Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials

The Antibody Mediated Prevention trials are assessing whether intravenously-administered VRC01 (10 mg/kg or 30 mg/kg vs placebo) can prevent HIV infection. In a modeling exercise, we used two models to predict the overall prevention efficacy (PE) of each VRC01 dose in preventing HIV infection. For t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hum Vaccin Immunother
Main Authors: Huang, Yunda, Karuna, Shelly, Carpp, Lindsay N., Reeves, Daniel, Pegu, Amarendra, Seaton, Kelly, Mayer, Kenneth, Schiffer, Joshua, Mascola, John, Gilbert, Peter B.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6183277/
https://ncbi.nlm.nih.gov/pubmed/29683765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1462640
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados